Opexa Therapeutics (OPXA) Misses Q2 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Opexa Therapeutics Reports Second Quarter 2016 Financial Results and Provides Corporate Update
August 11, 2016 4:01 PM EDTTHE WOODLANDS, TX -- (Marketwired) -- 08/11/16 -- Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, including Tcelna for multiple sclerosis (MS) and OPX-212 for neuromyelitis optica (NMO), today reported financial results for the quarter ended June 30, 2016, and provided an update on the Company's clinical development and corporate activities.
"During the second quarter we continued to advance our Phase 2b Abili-T trial in secondary progressive multiple sclerosis towards completion and we are excited to approach this significant milestone in the development of our personalized immunotherapy,... More
